Summary
Some treatments used for Parkinson's disease attenuate locomotor depression in rats treated with reserpine and α-methyl-p-tyrosine. In the present study memantine (2.5, 5.0mg/kg), amantadine (10, 20mg/kg) (both uncompetitive NMDA antagonists), and L-deprenyl (1.0, 5.0 mg/kg; MAO-B inhibitor) were tested for possible synergistic interactions with the dopamine agonists: bromocriptine (2.5, 5.0mg/kg) and L-DOPA (50, 100mg/kg, + benserazide, 100 mg/kg). At higher doses, memantine (10 mg/kg), amantadine (40 mg/kg), bromocriptine (5 and 10mg/kg) and L-DOPA (100, 200mg/kg) but not L-deprenyl (up to 10 mg/kg) produced a pronounced increase in locomotor activity when given alone. The combination of memantine, amantadine and L-deprenyl with bromocriptine did not result in synergism of action and, at best, an additive effect was seen. On the other hand the combination of these agents with L-DOPA produced a pronounced synergistic effect. Hence, the clinical observation that coadministration of L-DOPA with either memantine or amantadine results in enhancement of their action is also reflected in an animal model of Parkinson's disease. Such a combination therapy should allow the use of lower doses of both drugs which may reduce the occurrence of side effects and may also be predicted to have additional benefits related to the neuroprotective properties of memantine, amantadine, and L-deprenyl.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the antiakinetic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36: 303–326
Carlsson M, Carlsson A (1990) Interaction between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272–276
Chen HSV, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine — therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12: 4427–4436
Cohen G, Spina MB (1989) Deprenyl suppresses the axidant stress associated with increased dopamine turnover. Ann Neurol 26: 689–690
Coleman RJ (1992) Current drug therapy for Parkinson's disease. A review. Drugs Aging 2: 112–124
Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G (1994) Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J Neural Transm [PD Sect] (in press)
DiChiara G, Morelli M (1993) Dopamine acetylcholine glutamate interactions in the striaturn — a working hypothesis. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Parkinson's disease: from basic research to treatment. Raven Press, New York, pp 102–106
Feiling C (1973) The effect of adding amantadine to optimum L-DOPA dosage in Parkinson's syndrome. Acta Neurol Scand 49: 245–251
Goodwin P, Starr BS, Starr MS (1992) Motor responses to dopamine-Dl and dopamine-D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK-801. J Neural Transm [PD Sect] 4: 15–26
Greenamyre JT, O'Brien CF (1991) N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 48: 977–981
Jackisch R, Link T, Neufang B, Koch R (1992) Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine — no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 320: 21–42
Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian action of L-DOPA in monoamine-depleted rats. Ann Neurol 28: 539–546
Knoll J (1992) Pharmacological basis of the therapeutic effect of (−)deprenyl in age-related neurological diseases. Med Res Rev 12: 505–524
Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel — a human postmortem brain study. Eur J Pharmacol — Mol Pharmacol Sect 206: 297–300
Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Aman tadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl] 43: 91–104
Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263: 717–724
Maj J, Skuza G, Rogoz Z (1993 a) Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists in mice. Pol J Pharmacol 45: 349–360
Maj J, Skuza G, Rogoz Z (1993 b) Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. J Neural Transm [PD Sect] 6: 53–62
Messiha FS (1988) Effect of amantadine on chlorpromazine and reserpine-induced behavioral depression in the mouse. Neurosci Biobehav Rev 12: 219–222
Montastruc JL, Rascol O, Senard JM (1993) Current status of dopamine agonists in Parkinson's disease management. Drugs 46: 384–393
Morelli M, Febu S, DiChiara G (1992) Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-l and D-2 receptors. Neurochem Int 20 [Suppl]: 261S-264S
Olney J, Zorumski C, Stewart G, Price M, Wang G, Labruyere J (1990) Excitotoxicity of L-DOPA and 6-OH-DOPA: implications for Parkinson's and Huntington's diseases. Exp Neurol 108: 269–272
Rabey JM, Nissipeanu P, Korczyn AD (1992) Efficacy of memantine, and NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm [PD Sect] 4: 277–282
Rojas P, Altagracia M, Kravzov J, Rios C (1993) Amantadine increases striatal dopamine turnover in MPTP-treated mice. Drug Dev Res 29: 222–226
Schmidt WJ, Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32: 621–623
Schmidt WJ, Bubser M, Hauber W (1992) Behavioral pharmacology of glutamate in the basal ganglia. J Neural Transm [Suppl] 38: 65–89
Shoulson I (1992) An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. Eur Neurol 32: 46–53
Snell LD, Johnson KM (1985) Antagonism of N-methyl-D-aspartate-induced transmitter release in the rat striatum by phencyclidine-like drugs and its relationship to turning behavior. J Pharmacol Exp Ther 235: 50–57
Somalia PK, Nicklas WJ, Heikkila RE (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243: 398–400
Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-Parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213: 439–443
Svensson A, Carlsson A, Carlsson ML (1992) Differential locomotor interactions between dopamine D-l/D-2 receptor agonists and the NMDA antagonist dizocilpine in mono-amine-depleted mice. J Neural Transm [Gen Sect] 90: 199–217
Tilley JW, Kramer MJ (1981) Amantadine derivatives. In: Ellis GP, West GB (eds) Progress in medicinal chemistry, vol 18. Elsevier, Amsterdam, pp 1–44
Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H (1991) Protection of substantianigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349: 414–417
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Skuza, G., Rogoz, Z., Quack, G. et al. Memantine, amantadine, and L-deprenyl potentiate the action of L-DOPA in monoamine-depleted rats. J. Neural Transmission 98, 57–67 (1994). https://doi.org/10.1007/BF01277594
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01277594